Radiotherapy to intervention sites in mesothelioma: no more?  by Ceresoli, Giovanni Luca & Vavassori, Vittorio
Comment
www.thelancet.com/oncology   Vol 17   August 2016 1025
Malignant pleural mesothelioma is a tumour with 
a dismal prognosis, and its incidence is increasing 
worldwide as a result of widespread exposure to 
asbestos. Because of the pattern of tumour growth, 
the ipsilateral chest wall is often involved. Moreover, 
histological diagnosis is usually obtained by pleural 
biopsy, via video-assisted thoracoscopic surgery or 
other invasive procedures, which can result in tumour 
seeding at the site of the intervention. Chest wall 
involvement, including procedure-tract metastases, 
can lead to severe symptoms, mostly pain. Accordingly, 
local control in malignant pleural mesothelioma is a 
major challenge. 
Radiotherapy has been widely used in the past 
decades in the treatment of patients with malignant 
pleural mesothelioma, as a part of a multimodality 
therapy for early-stage disease,1,2 in the palliation of 
pain,3 and in the prophylaxis of track-site recurrence. 
Three small randomised trials4–6 assessed the role 
of prophylactic external-beam radiotherapy in 
reducing the frequency of thoracic procedure-tract 
metastases, and the results were conﬂ icting. In a 
French trial done in 1995,4 a signiﬁ cant reduction in 
tract malignant seeding with radiotherapy compared 
with no radiotherapy was reported, whereas two 
more recent studies from Australia5 and the UK6 found 
no beneﬁ t from the use of radiotherapy. When the 
data were pooled, there was insuﬃ  cient evidence to 
deﬁ nitively recommend prophylactic radiotherapy 
on thoracic diagnostic tracts.7 Limitations of these 
early trials include the heterogeneity of radiotherapy 
schedules and portal size—in the Australian study,5 
a single fraction of 10 Gy was delivered, whereas in 
the French and the UK studies4,6 patients were given 
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for maintenance therapy. Those patients who were 
minimal residual disease positive did not seem to 
beneﬁ t from maintenance therapy,5 suggesting that 
the depth of response during induction is driving 
the beneﬁ t (eg, patients who were minimal residual 
disease positive did not convert with maintenance 
therapy). Consequently, the relative contribution of 
the maintenance phase cannot be determined from 
the GADOLIN study design, a fact that would have 
been informed by including a non-maintenance 
control group. Additionally, the PRIMA study6 
identiﬁ ed ¹⁸F-ﬂ uorodeoxyglucose PET response at 
end of induction as a potential predictor for outcome; 
functional imaging data are unfortunately not available 
from the GADOLIN study. Finally, about 30% of patients 
seem to be refractory to both obinutuzumab plus 
bendamustine and bendamustine therapy at end of 
induction; characterising this group of patients and 
oﬀ ering alternative approaches should be the focus of 
future research.
Ultimately, obinutuzumab plus bendamustine 
followed by 2 years of maintenance obinutuzumab 
represents an attractive option for rituximab refractory 
patients, supporting a 2016 US FDA indication7 for 
obinituzumab based on these data, and establishing a 
new standard in this setting.
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a total dose of 21 Gy in three daily fractions. Of note, 
the incidence of procedure-tract metastases in the 
control group diﬀ ered between the French study and 
the other two trials (20% vs 10–12%), suggesting a 
bias in patient selection or that diﬀ erent methods 
were used for nodule assessment, or both. All three 
studies were done in an era when active chemotherapy 
with platinum–pemetrexed combinations was 
not available. However, despite the lack of any 
convincing evidence that prophylactic radiotherapy 
to intervention sites reduces subcutaneous nodule 
formation or improves quality of life, and the fact that 
it is not recommended by international guidelines,8 
this procedure has been extensively used in clinical 
practice.
The SMART trial investigators must be commended 
for having done an adequately powered open-
label, randomised trial, as Amelia Clive and 
colleagues report in The Lancet Oncology.9 This 
phase 3 trial assessed, as primary endpoint, whether 
prophylactic radiotherapy (given at a dose of 
21 Gy in three fractions over 3 working days, 
initiated within 42 days of the procedure after 
which the patient had been randomised) reduces the 
incidence of procedure-tract metastases in patients 
with malignant pleural mesothelioma, observed 
until 12 months or death. Patients randomised 
to the observation group could receive deferred 
radiotherapy at the same dose if a procedure-tract 
nodule was diagnosed during trial follow-up. 
Two independent observers examined the chest wall 
at any time point during the study. Of note, several 
secondary outcomes were analysed, including chest 
pain control, quality of life, and cost-effectiveness. 
The trial eligibility criteria were strict, as shown 
by the high screen failure rate (254 [56%] of the 
457 screened patients were not randomised). 
Intention-to-treat analysis showed no significant 
difference in the frequency of procedure-tract 
metastases between the groups receiving immediate 
and deferred radiotherapy (nine [9%] of 102 vs 
16 [16%] of 101, odds ratio 0·51 [95% CI 0·19–1·32]; 
p=0·14). Even more importantly, no difference 
was identified in quality of life, chest pain, and 
requirements of analgesic drugs between the two 
groups, suggesting that the use of prophylactic 
radiotherapy has no effect on symptom control or 
on patients’ perception of the natural history and 
progression of the disease. 
More than half of the enrolled patients received 
ﬁ rst-line pemetrexed–platinum chemotherapy during 
the study. Although patients were not stratiﬁ ed 
according to the addition of systemic treatment, its 
use was balanced between the two groups. Of note, 
patients who were not receiving chemotherapy had 
a signiﬁ cant reduction of procedure-tract metastasis 
risk by immediate radiotherapy (odds ratio 0·16 
[95% CI 0·02–0·93]; p=0·021). These data seem to 
suggest a beneﬁ t of chemotherapy on loco-regional 
disease control in malignant pleural mesothelioma. 
Although the data were derived from a subgroup 
analysis and should be conﬁ rmed by further studies, 
they are potentially relevant for clinical practice.
In conclusion, results from the SMART trial 
provide convincing evidence that the routine use of 
prophylactic radiotherapy to thoracic intervention sites 
is not justiﬁ ed in all patients with malignant pleural 
mesothelioma, although a beneﬁ t is suggested in 
patients who are not receiving chemotherapy. Together 
with the upcoming, similarly designed PIT trial,10 this 
study will establish the standard of practice in this 
setting.
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Historically, the detection of cancer in the dense breast 
has been a challenge for mammography. Although 
digital mammography, introduced in 2000, provided 
somewhat improved performance compared with 
ﬁ lm mammography,1 sensitivity is still not optimal in 
moderately dense to very dense breasts. Digital breast 
tomosynthesis (3D mammography) is a reﬁ nement of 
standard 2D digital mammography in which data from 
several low-dose x-ray images obtained over a range of 
angles around the breast are reconstructed to form a set 
of images of slices through the breast. By sequentially 
viewing this stack of image slices, the radiologist can 
better appreciate the 3D aspects of normal structures 
and lesions in the breast without the masking eﬀ ects 
that occur in conventional 2D projection radiographs 
due to superposition of tissue signals. Several studies 
have shown that 3D digital breast tomosynthesis, 
used in conjunction with 2D mammography, yields 
increased detection sensitivity, speciﬁ city, or both.2–4 
The contribution from 2D digital mammography seems 
to be mainly in providing complementary information 
about orientation and in depicting clustered 
microcalciﬁ cations. Furthermore, cancers identiﬁ ed 
on 3D mammography and not on 2D mammography 
have been suggested to be more likely to be those with 
potential to be lethal.5
The radiation dose to the breast from 3D 
mammography is roughly equal to that of 2D 
mammography, so women who receive the dual 
examination are in eﬀ ect receiving double the radiation 
dose of the standard 2D digital mammography 
assessment. Especially in population screening, in 
which large numbers of women would receive this 
additional exposure, a more dose-eﬃ  cient approach to 
imaging is desirable. In some countries where there is 
high concern regarding ionising radiation, the increased 
radiation dose might be regarded as prohibitive, 
thereby preventing  the use of 3D mammography for 
screening. 
The x-ray projection data gathered in the acquisition 
of the 3D digital breast tomosynthesis set can be used 
to create synthesised 2D mammograms and some 
manufacturers have created such images.6 If these are 
clinically acceptable, then the digital mammography 
procedure can be eliminated and the radiation dose for 
a complete digital breast tomosynthesis study can be 
reduced to that needed for a conventional 2D digital 
mammography examination.
In the Screening with Tomosynthesis OR standard 
Mammography-2 (STORM-2) trial reported in 
The Lancet Oncology,7 Daniela Bernardi and colleagues 
compare screening performance indicators between 
digital breast tomosynthesis (3D mammography) 
used in conjunction with 2D digital mammography 
and 3D mammography plus synthesised 2D 
mammograms. The images were acquired 
prospectively as part of the population screening 
programme in Trento, Italy. 9672 asymptomatic 
women aged 49 years or older who attended the 
screening programme were recruited for the study. By 
constructing a multi-group reader study, the authors 
were able to efficiently compare several different 
imaging strategies on the same women: conventional 
2D mammography versus 2D mammography plus 
3D mammography; conventional 2D mammography 
versus 2D synthetic mammography plus 3D 
mammography; 2D synthetic mammography versus 
2D synthetic mammography plus 3D mammography; 
and 2D mammography plus 3D mammography versus 
2D synthetic mammography plus 3D mammography. 
In each case, double reading was used, as it is the 
standard practice in most European screening 
programmes. 
Bernardi and colleagues report that the cancer 
detection rate for either combination strategy 
was higher than that for 2D mammography alone 
(cancer detection rates: 8·5 per 1000 screens 
[95% CI 6·7–10·5] for 2D–3D mammography and 
Reducing radiation doses for breast tomosynthesis?
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